Jun Bum Eum
University of Ulsan
12 Papers
143 Citations
Jun Bum Eum is an academic researcher from University of Ulsan. The author has contributed to research in topics: HBeAg & Hyperparathyroidism. The author has an hindex of 8, co-authored 12 publications.
Chat about Author
Papers
Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma
Do Hyun Park,Sang Soo Lee,So Eun Park,Jae-Lyun Lee,Jun-Ho Choi,Hee Jung Choi,Ji Woong Jang,Hyoung Jung Kim,Jun Bum Eum,Dong Wan Seo,Sung Koo Lee,Myung-Hwan Kim,Jung Bok Lee +12 more
TL;DR: P PDT plus S-1 was well tolerated and was associated with a significant improvement of overall survival and progression-free survival compared with PDT alone in patients with UHC, warranting further clinical investigation.
108
A Case of Acute Organotin Poisoning
Cheol In Yoo,Yangho Kim,Kyoung Sook Jeong,Chang Sun Sim,Nari Choy,Jongchul Kim,Jun Bum Eum,Yoshiaki Nakajima,Yoko Endo,Yu Jung Kim +9 more
TL;DR: A case with neurological manifestations similar to trialkyltin encephalopathy from the exposure to dimethyltin compounds is reported.
The Combined Measurement of Total Serum IgG and IgG4 May Increase Diagnostic Sensitivity for Autoimmune Pancreatitis Without Sacrificing Specificity, Compared With IgG4 Alone
Tae Jun Song,Myung-Hwan Kim,Sung-Hoon Moon,Jun Bum Eum,Do Hyun Park,Sang Soo Lee,Dong Wan Seo,Sung Koo Lee +7 more
TL;DR: The combined measurement of total serum IgG and IgG4 may increase diagnostic sensitivity without sacrificing specificity, compared with IgG 4 alone, however, the measurement of antinuclear antibody and rheumatoid factor may show no additional benefit when combined with total serum £1,800 mg/dl.
46
Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
J. W. Shin,Seok Won Jung,B. R. Park,C. J. Kim,Jun Bum Eum,Byung Gyu Kim,In Du Jeong,Sung-Jo Bang,S.-H. Lee,S. R. Kim,Neung-Hwa Park +10 more
TL;DR: Although the HBsAg level at baseline is often used to predict the antiviral potency of entecavir, on‐treatment HBV DNA and HBeAg levels are more helpful for prediction of subsequent clinical outcomes in H beAg‐positive chronic hepatitis B patients with entecvir treatment.
27
HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
Jung Woo Shin,Seok Won Jung,Bo Ryung Park,Chang Jae Kim,Jun Bum Eum,Byung Gyu Kim,In Du Jeong,Sung-Jo Bang,Neung Hwa Park +8 more
TL;DR: Although the HBV DNA level at baseline is often used to predict the antiviral potency of lamivudine and adefovir combination treatment in chronic hepatitis B patients with lamivUDine resistance, the results of this study suggest that theHBV DNAlevel at 24 weeks is a better marker for the virological response.
10